A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Phase 2 Completed 31 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.

Timeline

Start: 2020-10-30
Primary completion: 2021-05-27
Completion: 2021-05-27

Publications

Bergenstal RM, Bode BW, Bhargava A, Wang Q, Knights AW, Chang AM. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes. Diabetes Ther. 2023 Nov;14(11):1933-1945. doi: 10.1007/s13300-023-01476-4. Epub 2023 Sep 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Insulin Lispro	Protein / enzyme biologic	—	Subcutaneous
Subject	insulin degludec	Protein / enzyme biologic	—	Subcutaneous

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Summary

Timeline

Publications

Drugs

Indications